Merck (MRK) Tops Q2 EPS by 5c; Narrows and Raise FY15 EPS Outlook
- Dow ends at record high, Nasdaq falls as tech slides
- Trump's Facebook (FB) Ban Upheld, Oversight Board Asks Company to Come Up With a 'Proportionate Response' Going Forward
- PayPal (PYPL) Tops Q1 EPS by 21c, Offers Q2 and FY Guidance
- Peloton (PTON) Plunges After Recalling All Treadmills, Analyst Says Will Negatively Impact Broader Tread Rollout
- T-Mobile (TMUS) Gains After Topping Q1 Consensus as 5G Story Accelerates, 'More to Come' Says Analyst
Merck (NYSE: MRK) reported Q2 EPS of $0.86, $0.05 better than the analyst estimate of $0.81. Revenue for the quarter came in at $9.8 billion versus the consensus estimate of $9.8 billion.
Merck sees FY2015 EPS of $3.45-$3.55, versus the consensus of $3.45.
“We’re investing resources to grow our strongest brands and to support the most promising assets in our pipeline, while at the same time lowering our cost base and delivering operating leverage.”
“We’ve made significant progress this quarter in two of our most important assets, the KEYTRUDA and hepatitis C programs, and will be fully prepared to take advantage of these potentially breakthrough opportunities.”
“We’re witnessing the introduction of breakthrough therapies for some of the most difficult-to-treat diseases. Merck’s late-stage pipeline and ongoing launches reflect scientific and therapeutic progress with the potential to provide significant value to patients and society.”
For earnings history and earnings-related data on Merck (MRK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Q2 Holdings (QTWO) Tops Q1 EPS by 2c, Revenues Beat; Offers 2Q & FY21 Revenues Guidance Above Consensus
- Rent-A-Center (RCII) Tops Q1 EPS by 21c, Revenues Beat; Raises FY21 Revenues Guidance Above Consensus, FY21 EPS Mid-Point Views Above Consensus
- EPR Properties (EPR) Tops Q1 EPS by 18c, Revenues Beat
Create E-mail Alert Related CategoriesEarnings, Guidance, Hot Earnings, Hot Guidance, Management Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!